title: Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease.
abstract: Mendelian randomization data strongly suggest that hypertriglyceridemia (HTG) causes atherosclerotic cardiovascular disease (ASCVD), and so triglyceride (TG) level-lowering treatment in HTG is now more strongly recommended to address the residual ASCVD risk than has been the case in (generally earlier) published guidelines. Fibrates are the best-established agents for TG level lowering and are generally used as first-line treatment of TG levels greater than 500 mg/dL. Statins are the best-established agents for ASCVD prevention, and so are usually used as first-line treatment of TG levels less than 500 mg/dL.
authors.affiliation: Atherometabolic Research, Utah Foundation for Biomedical Research, 419 Wakara Way, Suite 211, Salt Lake City, UT 84108, USA. Electronic address: eliot.brinton@utah.edu.
authors.forename: Eliot A
authors.initials: EA
authors.lastname: Brinton
keywords: Atherosclerosis; Cardiovascular disease; Hypertriglyceridemia; Triglycerides